The Incremental Burden of Acute Respiratory Distress Syndrome: Long-term Follow-up of a Population-Based Nested Case-Control Study

2018 ◽  
Vol 93 (4) ◽  
pp. 445-452 ◽  
Author(s):  
Michelle Biehl ◽  
Adil Ahmed ◽  
Rahul Kashyap ◽  
Amelia Barwise ◽  
Ognjen Gajic
2006 ◽  
Vol 20 (5) ◽  
pp. 617-623 ◽  
Author(s):  
Francis Y Yao ◽  
Manjushree Gautam ◽  
Caren Palese ◽  
Raquel Rebres ◽  
Norah Terrault ◽  
...  

2019 ◽  
Vol 19 (10) ◽  
pp. e287-e288
Author(s):  
Margarita Blanes ◽  
Jose Ignacio Lorenzo ◽  
Paz Ribas ◽  
Ana Jiménez ◽  
José David González ◽  
...  

2017 ◽  
Vol 13 (4) ◽  
pp. 575-580 ◽  
Author(s):  
Andrés Navarrete ◽  
Ricard Corcelles ◽  
Gabriel Diaz del Gobbo ◽  
Sofía Perez ◽  
Josep Vidal ◽  
...  

2010 ◽  
Vol 90 ◽  
pp. 169
Author(s):  
R. BALLARIN ◽  
A. CUCCHETTI ◽  
M. SPAGGIARI ◽  
R. MONTALTI ◽  
F. DI BENEDETTO ◽  
...  

2016 ◽  
Vol 134 (6) ◽  
pp. 434-441 ◽  
Author(s):  
M. Veje ◽  
P. Nolskog ◽  
M. Petzold ◽  
T. Bergström ◽  
T. Lindén ◽  
...  

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S593-S594
Author(s):  
C Burgess ◽  
C Schnier ◽  
I Chalmers ◽  
R K Russell ◽  
R Hansen ◽  
...  

Abstract Background The risk of morbidity and mortality related to paediatric-onset inflammatory bowel disease (PIBD) and its treatment is a major concern to both patients and clinicians, especially when this may affect early adult life. We aimed to determine whether PIBD patients are at increased risk of ischaemic heart disease (IHD), stroke, cancer and death in a nationwide population-based study using administrative health data research methodology. Methods All children diagnosed with PIBD in Scotland 1981–2017 were identified within the Scottish Morbidity Record inpatient and day-case dataset (SMR01). PIBD cases were defined as any inpatient International Classification of Diseases (ICD) coding for Crohn’s disease (CD; 555/K50) or ulcerative colitis (UC; 556/K51) until age 16; 10% of cases were individually validated. A nested case-control study (1:3 ratio) matched for sex, age, postcode sector and deprivation quintile within the Scottish population was performed. Data-linkage was applied to SMR01, SMR06 (Scottish Cancer Registry) and NRS deaths datasets to identify any diagnosis of IHD, acute stroke, cancer or mortality. Cancer diagnoses were classified into potential disease related (small bowel, colonic, rectal, anal, hepatobiliary) or treatment related (lymphoma, leukaemia, myeloma, PTLD) cancers. Hazard ratios (HR) were calculated for each outcome using mixed effects Cox regression and the potential effect of sex, year of diagnosis and age at diagnosis were explored. Results The study population comprised 2484 children with PIBD and 7451 matched controls. Median age of PIBD diagnosis was 12 years (IQR 10–14) and age at end of follow-up 24 years (IQR 17–33) with 141,605 total person-years follow-up. Validation identified 242/261 true positive cases (positive predictive value 93%). 2 cases (0.08%) and 7 controls (0.09%) had an admission for IHD during follow-up (p = 0.845); 6 cases (0.24%) and 5 controls (0.07%) were admitted for stroke (p = 0.024). PIBD cases had a significantly higher risk of any cancer diagnosis (62 cases: 97 controls) HR 1.97 (p < 0.001), including a 31.9 times higher risk of disease-related cancers (p < 0.001) and a 6 times higher risk of treatment-related cancers (p = 0.011). The effect of PIBD on cancer risk was higher in males, but not related to year or age. PIBD cases had a greater risk of mortality (60 cases: 51 controls) HR 3.61 (p < 0.001). The specific mortality risk from infection was 21.4 times higher in PIBD cases (p = 0.004); the risk of suicide was 2.4 times higher but not statistically significant (p = 0.085). The effect of PIBD on mortality risk was not modified by sex, year or age. Conclusion Cancer and mortality are meaningful, serious early adult life adverse sequelae of PIBD however IHD and stroke occur infrequently.


2011 ◽  
Vol 91 (11) ◽  
pp. 1265-1272 ◽  
Author(s):  
Roberto Ballarin ◽  
Alessandro Cucchetti ◽  
Mario Spaggiari ◽  
Roberto Montalti ◽  
Fabrizio Di Benedetto ◽  
...  

2017 ◽  
Vol 51 (9) ◽  
pp. 757-767 ◽  
Author(s):  
Varda Shalev ◽  
Sarah Sharman Moser ◽  
Inbal Goldshtein ◽  
Jingbo Yu ◽  
Clara Weil ◽  
...  

Background: Hip fracture is a major complication of osteoporosis. Bisphosphonate medication is the mainstay of treatment for osteoporosis. However, concerns have been raised regarding the effectiveness of bisphosphonates in reducing hip fracture risk after long-term use, particularly among patients with suboptimal adherence. Objective: To examine the association between adherence with bisphosphonate therapy and long-term risk of hip fracture. Methods: Included in the present nested case-control study were osteoporotic women (n = 14 357) who initiated bisphosphonate therapy in 2000-2010 and were retrospectively followed for incident hip fracture through November 2014. Within this cohort, each case of primary hip fractures was individually matched to 3 controls without a primary hip fracture. Proportion of follow-up days covered (PDC) with bisphosphonates was calculated from bisphosphonate purchases. Adherence was categorized into the following groups: purchase of 1 or 2 months’ supply (reference group), at least 3 months’ supply to PDC ≤20%, PDC >20% to ≤80%, PDC >80% to ≤100%. Results: Included in the analysis were 426 case-control groups with a mean age (SD) of 73.7 years (7.9). Compared with the reference group, PDC of 80% to 100% with bisphosphonates was associated with a significant reduction in hip fracture risk for patients with 8 to 15 years of follow-up (OR = 0.39; 95% CI = 0.18-0.87). Among patients with a follow-up of up to 3 years, OR was 0.58 (95% CI = 0.31-1.06). Conclusions: Adherence with bisphosphonates among osteoporotic patients is associated with lower risk of hip fracture, with no indication of diminished effectiveness with long-term use.


Sign in / Sign up

Export Citation Format

Share Document